Enhanced Antiproliferative Activity of Docetaxel by Extremely Low Frequency Electromagnetic Fields in MCF-7 Breast Cancer Cells.

Pharmaceutics · 2025 · Mixed · Low evidence

← Research stream

MixedLow evidencePaper 5865

In MCF-7 cells, 50 μM docetaxel reduced viability by 50%, while combining 50 Hz, 20 mT ELF-EMF with docetaxel achieved a similar 50% viability reduction at a lower docetaxel concentration (14 μM). The combined treatment showed similar G2/M arrest and apoptoti…

Study snapshot

PublicationPharmaceutics · 2025

Study typein_vitro

Reported directionMixed

Evidence ratingLow

Abstract

: Breast cancer remains one of the leading causes of cancer-related mortality in women. While ongoing efforts seek new treatment options, improving the efficacy of existing therapies is equally crucial. Despite advancements in chemotherapy, severe side effects continue to limit treatment success. Combining therapies to enhance efficacy is a promising strategy. Emerging evidence suggests that electromagnetic fields (EMF) can act as chemotherapy enhancers, potentially allowing for lower drug doses. One proposed mechanism is the elevation of reactive oxygen species (ROS), which contributes to cell death. This study explores whether such enhancement exists for chemotherapeutics like docetaxel, where ROS is not the primary, but a contributing, mechanism of action. : We investigated the effects of 50 Hz, 20 mT extremely low-frequency EMF (ELF-EMF) exposure to MCF-7 breast cancer cells in the presence of docetaxel. Cytotoxicity was assessed using the MTT assay, while apoptosis, ROS generation, and cell cycle distribution were analyzed via flow cytometry. Morphological changes associated with apoptosis were examined using acridine orange/propidium iodide dual staining and fluorescence microscopy. : Results showed that 50 μM docetaxel reduced cell viability by 50%, while the combination of ELF-EMF and docetaxel achieved the same effect at a significantly lower docetaxel concentration (14 μM). Flow cytometry revealed similar G2/M phase arrest and apoptotic cell death in the combined treatment group, along with elevated ROS levels. : These findings suggest that ELF-EMF can potentiate the effects of docetaxel, even when ROS is not the dominant mechanism, supporting its potential as a complementary therapy in breast cancer treatment.

Machine Enhanced Logic

AI evidence extraction

Structured fields below were generated from the paper’s abstract and metadata to make the evidence easier to inspect. Automated extraction may be incomplete or incorrect; verify important details against the original paper.

Study typein_vitro

Effect directionmixed

PopulationMCF-7 breast cancer cells

Sample sizeNot supplied

ExposureELF · 5e-05 MHz

Evidence strengthLowConfidence: 78% · Peer reviewed: yes

Main findings

Outcomes measured

Cell viability/cytotoxicity (MTT)
Apoptosis (flow cytometry; AO/PI staining)
Reactive oxygen species (ROS) generation
Cell cycle distribution (G2/M arrest)
Morphological changes associated with apoptosis

Limitations

In vitro study in a single breast cancer cell line (MCF-7)
Exposure duration not reported in the abstract
No sample size/replication details reported in the abstract
Findings relate to chemotherapy potentiation rather than standalone EMF health effects

View raw extracted JSON

{
  "study_type": "in_vitro",
  "exposure": {
    "band": "ELF",
    "source": null,
    "frequency_mhz": 5e-05,
    "sar_wkg": null,
    "duration": null
  },
  "population": "MCF-7 breast cancer cells",
  "sample_size": null,
  "outcomes": [
    "Cell viability/cytotoxicity (MTT)",
    "Apoptosis (flow cytometry; AO/PI staining)",
    "Reactive oxygen species (ROS) generation",
    "Cell cycle distribution (G2/M arrest)",
    "Morphological changes associated with apoptosis"
  ],
  "main_findings": "In MCF-7 cells, 50 μM docetaxel reduced viability by 50%, while combining 50 Hz, 20 mT ELF-EMF with docetaxel achieved a similar 50% viability reduction at a lower docetaxel concentration (14 μM). The combined treatment showed similar G2/M arrest and apoptotic cell death, with elevated ROS levels.",
  "effect_direction": "mixed",
  "limitations": [
    "In vitro study in a single breast cancer cell line (MCF-7)",
    "Exposure duration not reported in the abstract",
    "No sample size/replication details reported in the abstract",
    "Findings relate to chemotherapy potentiation rather than standalone EMF health effects"
  ],
  "evidence_strength": "low",
  "confidence": 0.78,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "extremely low frequency electromagnetic fields",
    "ELF-EMF",
    "50 Hz",
    "20 mT",
    "docetaxel",
    "MCF-7",
    "breast cancer",
    "chemotherapy enhancement",
    "ROS",
    "apoptosis",
    "cell cycle"
  ],
  "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract and metadata and may be incomplete or incorrect. This material is for informational purposes and is not medical advice.

Identifiers and source

DOI: 10.3390/pharmaceutics17121505
PubMed: 41471021

Read the original paper →

Related papers

← Back to the Research Library